ONO Enters into Collaboration Agreement with Iktos

 Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO, Gyo Sagara; “Ono”) announced today that it entered into a collaboration agreement with Iktos (Paris, France; Chief Executive Officer, Yann Gaston-Mathé) to discover and develop a novel small molecule compounds using Iktos’s unique artificial intelligence (AI) drug discovery technology.

 Under the terms of the agreement, Iktos will apply its AI technology platform and know-how, helping to bring new insights and directions into the drug discovery process based on a comprehensive data-driven chemical structure generation technology complementing Ono’s drug discovery program to expedite the identification of novel small molecules against therapeutic targets selected by Ono. Ono will acquire exclusive worldwide rights to develop and commercialize small molecule compounds discovered in the collaboration. Iktos will receive research funding plus milestone payments based on achievement of research events from Ono.

 “Iktos has excellent AI technology and platform in drug discovery”, said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono. “Through this drug discovery collaboration, we are excited to work with Iktos to identify and develop the next generation of innovative treatments, leading to further expansion of our development pipeline.”

 "We are very pleased to collaborate with Ono, a leading pharmaceutical company based in Japan, and proud to announce our first collaboration deal with a Japanese pharma company’’ said Yann Gaston-Mathé, Co-founder & Chief Executive Officer of Iktos. “Our ultimate objective is to expedite drug discovery and achieve time and cost efficiencies for our collaborators by using Iktos’s proprietary AI platform and know-how. We are confident that we will be able to identify promising novel chemical matter for Ono’s drug discovery program.”

About Iktos

 Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis. More information on: